Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.37 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460881 | 1.00 | CXCR2 (0.55) | CXCR2DRD4SLC6A5KIFC1YAP1 | |
| SCHEMBL23461056 | 0.91 | CXCR2 (0.44) | CXCR2LMNA | |
| SCHEMBL23461057 | 0.91 | CXCR2 (0.44) | CXCR2LMNA | |
| SCHEMBL25557607 | 0.88 | CXCR2 (0.41) | CXCR2LMNA | |
| SCHEMBL25548975 | 0.88 | CXCR2 (0.41) | CXCR2LMNA | |
| SCHEMBL25548993 | 0.88 | CXCR2 (0.60) | CXCR2DRD4SLC6A5KIFC1LMNA | |
| SCHEMBL25553746 | 0.88 | CXCR2 (0.60) | CXCR2DRD4SLC6A5KIFC1LMNA | |
| SCHEMBL23461483 | 0.86 | CXCR2 (0.51) | CXCR2DRD4SLC6A5KIFC1YAP1 | |
| SCHEMBL23461484 | 0.86 | CXCR2 (0.51) | CXCR2DRD4SLC6A5KIFC1YAP1 | |
| SCHEMBL25556065 | 0.86 | CXCR2 (0.51) | CXCR2DRD4SLC6A5KIFC1YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113806-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885DRD4 4290/4885SLC6A5 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.